Benjamin Philip Levy
Johns Hopkins University · 306 works · 7,423 citations · h-index 34
Top works
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- Efficacy of Selpercatinib in RET -Altered Thyroid Cancers
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
- Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
- Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- 971TiP Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)
- Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
- Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
- Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
- Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline
- The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
- Safety, toleration, and pharmacokinetics of intravenous azithromycin
- Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
- Impact of Oncology Drug Shortages on Patient Therapy: Unplanned Treatment Changes
- ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
- Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non–Small-Cell Lung Cancer
- CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
- Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
- Persistent mutation burden drives sustained anti-tumor immune responses